Related Experiment Videos

Enalapril and hydrochlorothiazide as antihypertensive agents in the elderly

D A Shapiro1, C L Liss, J F Walker

  • 1Department of Clinical Research (Cardiovascular), Merck Sharpe & Dohme Research Laboratories, West Point, Pennsylvania 19486.

Insights

Enalapril and hydrochlorothiazide (HCTZ) effectively lower blood pressure in elderly patients with hypertension. Both medications demonstrated comparable efficacy and good tolerability in this study.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Hypertension is a prevalent condition in the elderly, increasing cardiovascular risk.
  • Effective blood pressure management is crucial for preventing complications in older adults.
  • Comparative studies of antihypertensive agents in this demographic are essential for guiding treatment decisions.

Purpose of the Study:

  • To compare the antihypertensive efficacy and tolerability of enalapril versus hydrochlorothiazide (HCTZ) in elderly patients.
  • To evaluate the effectiveness of these agents in both essential hypertension (EH) and isolated systolic hypertension (ISH).

Main Methods:

  • A randomized, double-blind, placebo-controlled study involving 174 elderly patients.
  • Patients received either enalapril or HCTZ, with dose adjustments and potential addition of the other drug if blood pressure remained uncontrolled.
  • Blood pressure measurements were taken at baseline, 8 weeks, and at the end of the study.

Main Results:

  • Both enalapril and HCTZ significantly reduced systolic and diastolic blood pressure in the elderly population (p ≤ 0.01).
  • Mean blood pressures at study end were comparable between enalapril (144/83 mm Hg) and HCTZ (145/83 mm Hg).
  • Caucasian patients showed a greater systolic blood pressure reduction with enalapril after 4 weeks (p ≤ 0.05).

Conclusions:

  • Enalapril and HCTZ are both effective antihypertensive treatments for elderly individuals.
  • The drugs were generally well-tolerated, with no significant difference in laboratory adverse experiences.
  • Both agents offer a valuable therapeutic option for managing hypertension in the elderly population.

Related Concept Videos